Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

The following is a summary of “Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a newer class of medications used to treat type 2 diabetes. These ...

Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. SGLT2 inhibitors reduce effectively fasting and postprandial ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

A reduction was seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a newer group of drugs that help manage diabetes. These drugs work by ...

"To our knowledge, this is the first study to evaluate diabetic retinopathy progression using data generated from clinical ...